Thus, CSN5 depletion exhibits the biological and biochemical effects shown for doxycycline treatment in DLBCL cells, consistent with the suggestion that CSN5 is a critical target of the antineoplastic action of doxycycline in DLBCL cells. The gene discussed is COPS5; the disease is diffuse large B-cell lymphoma.